4.7 Article

On the spot immunocapture in targeted biomarker analysis using paper-bound streptavidin as anchor for biotinylated antibodies

期刊

ANALYTICAL AND BIOANALYTICAL CHEMISTRY
卷 414, 期 19, 页码 5979-5989

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00216-022-04161-w

关键词

Antibodies; Tailor-made; Smart sampler; Pretreatment; Universal anchor; Biotin

资金

  1. University of Oslo (incl Oslo University Hospital)
  2. A4B project - Horizon 2020 Marie Sklodowska-Curie Action ITN 2017 of the European Commission [765502]
  3. Research Council of Norway INFRASTRUKTUR-program [295910]

向作者/读者索取更多资源

The study introduces a novel on-paper device combining sample collection with affinity sample pretreatment. The functionality of the device has been demonstrated in the laboratory setting, showing potential for detecting low abundant biomarkers.
The modification of an easily available resource like paper to circumvent expensive or intensive sample pretreatment could be the answer to sample analysis in resource-poor regions. Therefore, a novel on-paper device combining sample collection with affinity sample pretreatment is introduced here. Universal smart affinity samplers are produced by a simple KIO4-mediated oxidation of cellulose, which functionalizes the paper. This is followed by immobilization of streptavidin. Streptavidin serves as a universal anchor for biotinylated antibodies, enabling simple preparation of tailor-made affinity samplers. The functionality of the device was tested using a model protein (human chorionic gonadotropin, hCG) and biotinylated anti-hCG antibodies for affinity capture. In a laboratory setting, the performance was demonstrated, and a 14-fold increase of target binding compared to binding without bmAb was achieved. The recovery of hCG captured with bmAb-treated samplers was determined to be 33% and comparable to previously described affinity capture approaches. Application of the smart affinity samplers to human serum containing hCG showed an R-2 of 0.98 (200-1000 pg mL(-1)), precision of <= 9.1% RSD, and estimated limit of detection of 65 pg mL(-1). Although further optimization and validation are necessary prior to application to real samples in clinical settings, the potential of the device for use in determination of low abundant biomarkers in complex samples has been demonstrated.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据